Mr. David Judd, a consultant cellular biologist, and Chief Executive Officer of Pharmacyte Biotech Inc (OTCMKTS:PMCB), Kenneth L. Waggoner will visit the GMP production facility of Austrianova in Bangkok, Thailand. They will oversee the production of a clinical trial material to treat non-metastatic and locally advanced inoperable pancreatic cancer. Judd and Wagonner will witness the culturing of genetically changed HEK-293 cells before and after the encapsulation process.
Expertise of Judd
Judd has experience in developing cell culture media for several cell lines and primary cells. He has knowledge in HEK-293 cells growth. Judd’s credits include development of cell assays, manufacturing processes, downstream recovery strategies, cell culture processes, and biochemical analysis.
The company has requested the on-site presence of Judd to help correct any problems in the manufacturing process because the most recent two staggered processes are already completed.
Waggoner said they are on track after incorporating changes in the manufacturing process and proceed with CypCaps GMP production. He felt that their presence is necessary at the site to oversee the entire process during production of the clinical material for non-metastatic and locally advanced inoperable pancreatic cancer. It ensures they are on the path and within the time limit to submit IND (investigational new drug) application. Therefore, the presence of Judd is an absolute necessity because the two manufacturing processes are conducted in a staggered manner.
Interview in Thailand
There is a possibility to interview Austrianova’s Dr. Brian Salmons, Prof. Dr. Walter H. Günzburg, Judd, and Waggoner on the progress of production of clinical material for trial while in Bangkok. The interviewers may ask details of the factors involved in the production process, and clinical trial product testing in submitting IND.
Pharmacyte may post the interviews, images, and videos on social media while CEO and Judd are on at the site. Interested parties in the content can visit the social media platforms of the company.
Cannabinoid therapy for cancer
The University of Northern Colorado, the partner of Pharmacyte, bioengineered the human cell line for activating cannabinoid pro drug. The main aim is to develop a cannabinoid therapy to cure brain cancer. In the next step, it will test the transfected cells efficiency in altering the cannabinoid drugs into the active cancer treatment form.